A moving target: challenges in treating BRAF-mutant colorectal cancer

被引：0
|
作者：
Scott, Aaron J. [1 ]
Leong, Stephen [1 ]
Messersmith, Wells A. [1 ]
Lieu, Christopher H. [1 ]
机构：
[1] Univ Colorado, MS8117,12801 E 17th Ave,Room 8122, Aurora, CO 80024 USA
来源：
COLORECTAL CANCER | 2013年 / 2卷 / 03期
关键词：
D O I：
10.2217/CRC.13.23
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Biomarker-oriented clinical studies have shown mounting evidence for improved efficacy with targeted therapy. Unfortunately, single-agent BRAF inhibition has shown limited efficacy in patients with metastatic BRAF-mutant colorectal cancer. Multiple mechanisms for potential BRAF inhibitor resistance demonstrate the complex biology behind tumorigenesis in colorectal cancer and highlight the obstacles of acquired and intrinsic drug resistance in treating this disease. Biomarker-related strategies with potential predictive value for specific molecular anomalies offer the possibility for improved targeted agents and rational combinations. Synthetic lethality gene array has become a major focus in current research for developing such agents. Combination therapy based on molecular profiles may further enhance individualized patient care.
引用
收藏
页码：197 / 204
页数：8
相关论文
共 50 条
  • [1] Hitting the Target in BRAF-Mutant Colorectal Cancer
    Nagaraja, Ankur K.
    Bass, Adam J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 3990 - +
  • [2] THE MAPK PATHWAY IS A THERAPEUTIC TARGET IN BRAF-MUTANT COLORECTAL CANCER
    不详
    [J]. CANCER DISCOVERY, 2015, 5 (11) : 1122 - 1122
  • [3] Management of BRAF-mutant metastatic colorectal cancer
    Burge, Matthew
    Whitehall, Vicki
    [J]. COLORECTAL CANCER, 2016, 5 (04) : 131 - 133
  • [4] Targeted therapy for BRAF-mutant colorectal cancer
    Gunjur, Ashray
    [J]. LANCET ONCOLOGY, 2019, 20 (11): : E618 - E618
  • [5] Molecular targeted therapy of BRAF-mutant colorectal cancer
    Ducreux, Michel
    Chamseddine, Ali
    Laurent-Puig, Pierre
    Smolenschi, Cristina
    Hollebecque, Antoine
    Dartigues, Peggy
    Samallin, Emmanuelle
    Boige, Valerie
    Malka, David
    Gelli, Maximiliano
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [6] BRAF-mutant colorectal cancer, a different breed evolving
    Lai, Eleonora
    Pretta, Andrea
    Impera, Valentino
    Mariani, Stefano
    Giampieri, Riccardo
    Casula, Laura
    Pusceddu, Valeria
    Coni, Pierpaolo
    Fanni, Daniela
    Puzzoni, Marco
    Demurtas, Laura
    Ziranu, Pina
    Faa, Gavino
    Scartozzi, Mario
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2018, 18 (06) : 499 - 512
  • [7] Kinase Inhibitor in a Patient with BRAF-mutant Colorectal Cancer
    Sakumura, Miho
    Ando, Takayuki
    Ueda-Consolvo, Tomoko
    Motoo, Iori
    Mihara, Hiroshi
    Kajiura, Shinya
    Teramoto, Akira
    Nanjo, Sohachi
    Fujinami, Haruka
    Yasuda, Ichiro
    [J]. INTERNAL MEDICINE, 2022, 61 (11) : 1707 - 1712
  • [8] Treatment options in BRAF-mutant metastatic colorectal cancer
    Bernabe-Ramirez, Carolina
    Patel, Rajvi
    Chahal, Jaspreet
    Saif, Muhammad Wasif
    [J]. ANTI-CANCER DRUGS, 2020, 31 (06) : 545 - 557
  • [9] Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer
    Lee, Hey Min
    Morris, Van
    Napolitano, Stefania
    Kopetz, Scott
    [J]. ONCOLOGY-NEW YORK, 2019, 33 (06): : 206 - 211
  • [10] Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
    Grassi, Elisa
    Corbelli, Jody
    Papiani, Giorgio
    Barbera, Maria Aurelia
    Gazzaneo, Federica
    Tamberi, Stefano
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
12345